June 11 (Reuters) - Novavax Inc said on Friday its COVID-19 vaccine candidate showed immune response and protection against the SARS-CoV-2 Beta variant, which was originally identified in South Africa, in three animal and human studies. (Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli)
Market Closed -
Other stock markets
|
Pre-market 04:40:39 pm | |||
15.52 USD | +0.10% | 14.94 | -3.67% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+223.23% | 2.18B | |
+54.05% | 58.71B | |
-2.02% | 41.31B | |
+37.01% | 39.2B | |
-10.22% | 27.4B | |
+13.42% | 26.55B | |
-21.60% | 18.98B | |
+2.89% | 12.51B | |
+22.40% | 11.94B | |
+27.49% | 12.08B |
- Stock Market
- Equities
- NVAX Stock
- News Novavax, Inc.
- Novavax : says COVID-19 vaccine candidate shows immune response against Beta variant